Inogen, Inc. (INGN) announced on Monday that it has received clearance from the U.S. Food and Drug Administration (FDA) for its SIMEOX 200 Airway Clearance Device. This device is aimed at assisting patients suffering from chronic lung diseases characterized by excessive mucus production and retention.
The SIMEOX 200 enhances bronchial drainage by facilitating the movement of bronchial secretions. It achieves this through high-frequency oscillatory vibrations combined with intermittent negative pressure applied to the airways during exhalation, as stated by the company.
Inogen plans to initiate a limited release of the SIMEOX 200 in specifically selected locations in 2025.
Prior to the market opening, Inogen's shares are trading at $8.90 on the Nasdaq, reflecting an increase of 3.73 percent.
